Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of glucoprotein for pharmaceuticals

A fetuin and drug technology, applied in the field of new pharmaceutical uses of fetuin, can solve problems such as unclear functions and uses

Active Publication Date: 2008-04-16
SHUITA BEIJING MATURE VINEGAR BIOSCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Although fetuin was discovered in 1944, its function and use are not well understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of glucoprotein for pharmaceuticals
  • Use of glucoprotein for pharmaceuticals
  • Use of glucoprotein for pharmaceuticals

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0011] Experimental Example 1: Effect of Fetuin on the Infarct Size of Focal Cerebral Ischemia

[0012] 1. Animal grouping: 88 SD male rats, weighing 250g-350g, were randomly divided into 10 groups, 8 in each group. Groups 1 and 6 were model control groups, and the rest were treatment groups with different doses and administration times.

[0013] 2. Operation steps: Fetuin (fetuin) was dissolved in normal saline (1ml volume), and intravenously injected into rats at 15 minutes and 30 minutes after ischemia respectively (see Table 1).

[0014] Table 1 The effect of fetuin on the infarct size of focal cerebral ischemia

[0015]

[0016] After 24 hours of focal cerebral ischemia in rats, the animals were anesthetized and sacrificed, the brain was removed and fixed, cut into 2mm thick brain slices, immersed in 2% TTC (2,3,5-hiphenyltetrazoliam chloride) and incubated at 37°C 30 minutes. After the stained brain tissue was photographed, the cerebral infarct area was calculated ...

experiment example 2

[0019] Experimental example 2: Effect of fetuin on the expression of activated microglial cells and macrophages in rats with acute ischemic brain injury

[0020] 1. Grouping of animals: 12 male SD rats, weighing 250-350 grams, were randomly divided into 2 groups: Group 1 was a fetuin treatment group, Group 1 was a model control group, 6 rats in each group.

[0021] 2. Operation steps: Fetuin (fetuin) was dissolved in normal saline (1ml volume), and intravenously injected into the treatment group rats (50mg / kg) 15 minutes after ischemia, and the model group was only injected with the same amount of normal saline. After 24 hours the animals were anesthetized and the rats (approximately 350 ml) were perfused via the left ventricle with 4% paraformaldehyde (pH 7.4). The brain was taken out, cut into 2mm thick brain slices, fixed with the same fixative solution at 4°C for 12 hours, and then put into 30% sucrose solution for 12 hours (4°C). Frozen sections (10 μm). Immunohistochem...

experiment example 3

[0024] Experimental Example 3: Effect of Fetuin on the Expression of Tumor Necrosis Factor-α (TNF-α) in the Rat Ischemic Brain Injury Area

[0025] 1. Grouping of animals: the same as in Experimental Example 2;

[0026] 2. Operation steps: Fetuin (fetuin) was dissolved in normal saline (volume 1ml), and intravenously injected into the treatment group rats (50 mg / kg) within 15 minutes after ischemia, and the model group was only injected with the same amount of normal saline. Anesthetize the animal 24 hours later, perfuse the artery (about 300ml) with normal saline through the left ventricle, take out the brain, cut into 2mm brain slices, collect the ischemic injured tissue on ice, add lysis buffer to make a homogenate, and place on ice Let stand for 30 minutes and centrifuge (4°C, 2000g). The supernatant was collected, and the protein content was determined. After SDS-page electrophoresis, it was transferred to a nitrocellulose membrane, and the TNF-α content was detected by ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a new pharmaceutic application of glucoprotein. In particular, it relates to application of fetuin fetua, AHSG in the preparation of medicine for curing cerebral ischemia injury including cerebral thrombosis, cerebral infarction and cerebral hemorrhage.

Description

field of invention [0001] The present invention relates to a new pharmaceutical application of glycoprotein, in particular to fetuin (fetuin, α 2 -New pharmaceutical application of HS glycoprotein, molecular weight 45kda--65kda). Background technique [0002] Fetuin (fetuin, α 2 -HS glycoprotein, molecular weight 45kda--65kda) is a glycoprotein synthesized by the liver, which is widely present in mammalian (including human, cow, mouse, etc.) for high. Bovine fetuin is nearly 30% sugar and contains 2 N-terminal and a relatively small C-terminal region. [0003] Although fetuin (fetuin) was discovered in 1944, its function and use are not well understood. It has been reported in the literature that fetuin can increase cell growth rate and protein expression. Because it inhibits the activity of proteolytic enzymes in cell culture, it can strengthen the contact between cells and the extension of cells. Currently, fetuin (fetuin) is mainly used in cell culture, especially i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61P25/00A61P7/02A61P9/10C07K14/435C07K14/47
Inventor 车建途图娅
Owner SHUITA BEIJING MATURE VINEGAR BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com